Please assess the completion status of the following clinical trial:

Trial Title: Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven cases of breast cancer~Exclusion Criteria:~* Patients with onlybenign lesion~* Patients with onlyductal carcinomain situ (DCIS)~* Patients with recurrent/ residual breast cancer in same breast~* Pregnant women~* Lactating Women6.Patients with ferromagnetic or otherwise non-MRI compatible aneurysm clips.~* The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator~* Patients with contraindications for MRIdue to embedded foreign metallic objects. Bullets, shrapnel, metalwork fragments, or other metallic material adds unnecessary risk to the patient.~* Known history of severe claustrophobia~* Patients under the age of 18~* For patients with known history of allergic reaction to MR contrast material or abnormal kidney function (GFR \< 40 mL/ min), a contrast enhanced exam will not be performed; however, a non-contrast exam may be performed in these patients.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3D MR Fingerprinting scan (Type: EXPERIMENTAL): Three separate 3D MR fingerprinting scans: Before the start of chemotherapy, 7-10 days after the first cycle of chemotherapy, and within 1 month of the end of chemotherapy treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).